Loading cancer entity…
Loading cancer entity…
Clinical trials
3,384 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (537)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT01177371 | High-Dose Busulfan and High-Dose Cyclophosphamide Followed By Donor Bone Marrow Transplant in Treating Patients With Leukemia, Myelodysplastic Syndrome, Multiple Myeloma, or Recurrent Hodgkin or Non-Hodgkin Lymphoma | completed | Phase 2 | 13 | Case Comprehensive Cancer CenterOTHER | 1 | Aug 9, 2010 | clinicaltrials |
| NCT00083460 | Study of Combination PS-341 and Thalidomide in Multiple Myeloma | completed | Phase 1 | 86 | University of ArkansasOTHER | 1 | Aug 2, 2010 |
| clinicaltrials |
| NCT00794261 | Stem Cell Mobilization With Pegfilgrastim in Lymphoma and Myeloma(PALM) | completed | Phase 2 | 150 | Centre Leon BerardOTHER | 1 | Jul 8, 2010 | clinicaltrials |
| NCT00083538 | Study of Tumor Antigen-Pulsed Autologous Dendritic Cell Vaccination Administrated Subcutaneously or Intranodally | completed | Phase 2 | 40 | University of ArkansasOTHER | 1 | Jul 7, 2010 | clinicaltrials |
| NCT00083408 | Combination Bisphosphonate and Anti-Angiogenesis Therapy With Pamidronate and Thalidomide | completed | Phase 2 | 20 | University of ArkansasOTHER | 1 | Jul 5, 2010 | clinicaltrials |
| NCT00081757 | An Open Protocol for the Compassionate Use of Thalidomide | completed | Phase 1 / Phase 2 | 250 | University of ArkansasOTHER | 1 | Jul 2, 2010 | clinicaltrials |
| NCT00083577 | Anti-Angiogenesis Therapy Using Thalidomide in Multiple Myeloma | completed | Phase 2 | 250 | University of ArkansasOTHER | 1 | Jul 2, 2010 | clinicaltrials |
| NCT00083681 | DCEP in Combination With Thalidomide as Salvage Therapy for Post Transplantation Relapse | completed | Phase 2 | 180 | University of ArkansasOTHER | 1 | Jul 2, 2010 | clinicaltrials |
| NCT00083876 | D.T. PACE Versus High Dose Melphalan and Autologous Transplant in Patients With Previously Treated Multiple Myeloma | completed | Phase 3 | 500 | University of ArkansasOTHER | 1 | Jul 2, 2010 | clinicaltrials |
| NCT00083902 | Dexamethasone or Dexamethasone in Combination With Thalidomide as Salvage Therapy | completed | Phase 2 | 190 | University of ArkansasOTHER | 1 | Jul 2, 2010 | clinicaltrials |
| NCT00093028 | Study of Bortezomib and Revlimid™ for Patients Relapsing or Progressing on Total Therapy II | completed | Phase 3 | 315 | University of ArkansasOTHER | 1 | Jul 2, 2010 | clinicaltrials |
| NCT00193557 | Weekly Bortezomib (Velcade) in the Treatment of Patients With Refractory Multiple Myeloma | completed | Phase 2 | 40 | SCRI Development Innovations, LLCOTHER | 1 | Jun 29, 2010 | clinicaltrials |
| NCT00417911 | Efficacy of Bortezomib Consolidation After High-dose Melphalan With Stem Cell Support in Myeloma Patients | completed | Phase 3 | 400 | Nordic Myeloma Study GroupOTHER | 5 | Jun 22, 2010 | clinicaltrials |
| NCT01016548 | Evaluation of Influenza H1N1 Vaccine in Adults With Lymphoid Malignancies on Chemotherapy | completed | Phase 3 | 42 | University Health Network, TorontoOTHER | 1 | Jun 4, 2010 | clinicaltrials |
| NCT00222053 | IFM 99-02 Thalidomide in Myeloma | completed | Phase 3 | 800 | University Hospital, ToulouseOTHER | 1 | Apr 2, 2010 | clinicaltrials |
| NCT00179647 | Expanded Access Program:Lenalidomide With or Without Dexamethasone In Previously Treated Subjects With Multiple Myeloma | completed | Phase 3 | 1,913 | Celgene CorporationINDUSTRY | 2 | Mar 16, 2010 | clinicaltrials |
| NCT01085058 | Predictive Value of the "Cytocapacity Test" Patients With Lymphoproliferative Diseases and High-dose Therapy(CU01) | completed | Phase 2 / Phase 3 | 169 | WiSP Wissenschaftlicher Service Pharma GmbHOTHER | 0 | Mar 11, 2010 | clinicaltrials |
| NCT01070862 | Multiple Myeloma Treated With Thalidomide Before Autotransplant or With Conventional Chemotherapy and as Consolidation/Maintenance Treatment in Young and Elderly Patients : 3 Randomized Studies.(MAG 2002) | completed | Phase 3 | — | University Hospital, CaenOTHER | 1 | Feb 18, 2010 | clinicaltrials |
| NCT00459069 | The Use of Dendritic Cell/Tumor Fusions as a Novel Tumor Vaccine in Patients With Multiple Myeloma | completed | Phase 1 | 18 | Beth Israel Deaconess Medical CenterOTHER | 1 | Jan 12, 2010 | clinicaltrials |
| NCT00229203 | A Study of Aplidin (Plitidepsin) 3 h iv in Subjects With Relapsing or Refractory Multiple Myeloma | completed | Phase 2 | 51 | PharmaMarINDUSTRY | 1 | Dec 24, 2009 | clinicaltrials |
| NCT00195533 | Study Comparing Piperacillin-tazobactam Versus Piperacillin-tazobactam Plus Glycopeptide in Neutropenic Patients | completed | — | 801 | Wyeth is now a wholly owned subsidiary of PfizerINDUSTRY | 1 | Nov 16, 2009 | clinicaltrials |
| NCT00988312 | Dendritic Cells(DC)-Based Id Vaccination in Stage-I Myeloma | completed | Phase 1 | 9 | University Hospital Carl Gustav CarusOTHER | 1 | Oct 2, 2009 | clinicaltrials |
| NCT00051116 | A Phase II Study of Continuous Versus Syncopated Dosing of CC-5013 for the Treatment of Refractory Multiple Myeloma | completed | Phase 2 | 100 | Celgene CorporationINDUSTRY | 1 | Sep 23, 2009 | clinicaltrials |
| NCT00425347 | Phase I, Multi-Center, Open-Label, Dose Escalation Study of HuLuc63 in Subjects With Advanced Multiple Myeloma | completed | Phase 1 | 35 | Facet BiotechINDUSTRY | 1 | Sep 23, 2009 | clinicaltrials |
| NCT00391157 | VELCADEXA: Velcade and Dexamethasone in Multiple Myeloma | completed | Phase 2 | 40 | PETHEMA FoundationOTHER | 1 | Sep 18, 2009 | clinicaltrials |
| NCT00461747 | GEM05 for Patients With Multiple Myeloma Under 65 Years(GEM05MENOS65) | completed | Phase 3 | 390 | PETHEMA FoundationOTHER | 1 | Sep 18, 2009 | clinicaltrials |
| NCT00186316 | Vaccine Therapy for Multiple Myeloma Utilizing Idiotype-Pulsed Allogeneic Dendritic Cells | completed | Phase 1 / Phase 2 | 30 | Stanford UniversityOTHER | 1 | Aug 25, 2009 | clinicaltrials |
| NCT00327249 | Safety and Efficacy Study of Imexon for Treatment of Multiple Myeloma Patients | completed | Phase 1 / Phase 2 | — | AmpliMed CorporationINDUSTRY | 1 | Aug 11, 2009 | clinicaltrials |
| NCT00306813 | Evaluation of Lenalidomide, Doxorubicin and Dexamethasone (RAD) in Patients With Relapsed or Refractory Multiple Myeloma | completed | Phase 1 / Phase 2 | 53 | University of WuerzburgOTHER | 1 | Aug 4, 2009 | clinicaltrials |
| NCT00950768 | Melphalan 200 mg/m2 Versus Melphalan 100 mg/m2 in Newly Diagnosed Myeloma Patients | completed | Phase 3 | 298 | Azienda Ospedaliera San Giovanni BattistaOTHER | 0 | Aug 3, 2009 | clinicaltrials |
| NCT00436059 | The Efficacy of Velcade on Bone Tissue During Myelomatosis (Bone Marrow Cancer) | completed | Phase 2 | 20 | Vejle HospitalOTHER | 1 | Jul 8, 2009 | clinicaltrials |
| NCT00910078 | Serum Free Light Change in Multiple Myeloma | completed | — | — | Azienda Ospedaliera San Giovanni BattistaOTHER | 1 | May 29, 2009 | clinicaltrials |
| NCT00781170 | Dose-Reduced Allogeneic Stem Cell Transplantation After Autologous High-Dose Chemotherapy in Patients With Multiple Myeloma | completed | Phase 2 | 20 | Universitätsklinikum Hamburg-EppendorfOTHER | 0 | May 28, 2009 | clinicaltrials |
| NCT00036023 | Chemotherapy Related Anemia in Patients With Non-Myeloid Malignancies | completed | Phase 2 | — | AmgenINDUSTRY | 0 | May 11, 2009 | clinicaltrials |
| NCT00080405 | Repeat-Dose Pharmacokinetics and Pharmacodynamics of Bortezomib in Patients With Relapsed Multiple Myeloma | completed | Phase 1 | 40 | Millennium Pharmaceuticals, Inc.INDUSTRY | 0 | Mar 27, 2009 | clinicaltrials |
| NCT00111319 | VELCADE/Melphalan/Prednisone Versus Melphalan/Prednisone in Patients With Previously Untreated Multiple Myeloma | completed | Phase 3 | — | Millennium Pharmaceuticals, Inc.INDUSTRY | 1 | Mar 26, 2009 | clinicaltrials |
| NCT00592579 | A Phase 2 Study With Panzem in Patients With Relapsed or Plateau Phase Multiple Myeloma | completed | Phase 2 | 60 | CASI pharmaceuticals, Inc.INDUSTRY | 1 | Feb 26, 2009 | clinicaltrials |
| NCT00200681 | IFM 2005-01: Velcade/Dexamethasone Versus Vincristine/Adriamycin (Doxorubicin)/Dexamethasone (VAD) for the Treatment of Patients With Multiple Myeloma | completed | Phase 3 | 493 | Nantes University HospitalOTHER | 1 | Feb 5, 2009 | clinicaltrials |
| NCT00291538 | Comparison of Pharmacokinetics and Pharmacodynamics of Subcutaneous Versus Intravenous Administration of Bortezomib in Patients With Multiple Myeloma | completed | Phase 1 | 20 | Nantes University HospitalOTHER | 1 | Feb 4, 2009 | clinicaltrials |
| NCT00207805 | The Optimal Timing of a Second Autologous Peripheral Blood Stem Cell Transplantation in Patients (<61 Years) With Multiple Myeloma | completed | Phase 3 | 202 | Centre National de Greffe de Moelle OsseuseOTHER_GOV | 1 | Jan 27, 2009 | clinicaltrials |
| NCT00516152 | Phase II Study Evaluating Busulfan and Fludarabine as Preparative Therapy in Adults With Hematopoietic Disorders Undergoing MUD SCT | completed | Phase 2 | 36 | University of California, San FranciscoOTHER | 1 | Jan 26, 2009 | clinicaltrials |
| NCT00193544 | Arsenic Trioxide and Thalidomide in the Treatment of Refractory Multiple Myeloma | completed | Phase 2 | 40 | SCRI Development Innovations, LLCOTHER | 0 | Jan 23, 2009 | clinicaltrials |
| NCT00579917 | Behavioral Intervention For BMT/SCT Survivors(BMT/SCT) | completed | — | 133 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Jan 7, 2009 | clinicaltrials |
| NCT00560053 | Pethema Multiple Myeloma 2000 | completed | Phase 3 | 500 | PETHEMA FoundationOTHER | 0 | Nov 27, 2008 | clinicaltrials |
| NCT00113204 | Safety Study of IPI-504 in Patients With Relapsed and Relapsed Refractory Multiple Myeloma(IPi-504-01) | completed | Phase 1 | 18 | Infinity Pharmaceuticals, Inc.INDUSTRY | 1 | May 20, 2008 | clinicaltrials |
| NCT00320476 | VTD Followed By MPT Maintenance As a First Line Treatment For The Patients With MM Who Are Non-Transplant Candidates | completed | Phase 2 | 35 | Korean Multiple Myeloma Working PartyOTHER | 1 | May 6, 2008 | clinicaltrials |
| NCT00633542 | Maintenance Therapy After Thalidomide-Dexamethasone(ThaDD) for Multiple Myeloma(MM) | completed | Phase 3 | 103 | Università Politecnica delle MarcheOTHER | 1 | Mar 12, 2008 | clinicaltrials |
| NCT00001750 | Comparing Treatments for Multiple Myeloma | completed | Phase 2 | 32 | National Heart, Lung, and Blood Institute (NHLBI)NIH | 1 | Mar 4, 2008 | clinicaltrials |
| NCT00257114 | Evaluation of VELCADE Given as Retreatment to Multiple Myeloma Patients for Efficacy, Safety and Tolerability | completed | Phase 4 | — | Millennium Pharmaceuticals, Inc.INDUSTRY | 1 | Feb 11, 2008 | clinicaltrials |
| NCT00116441 | Vaccination in the Peripheral Stem Cell Transplant Setting for Multiple Myeloma | completed | Phase 1 / Phase 2 | 22 | Cell GenesysINDUSTRY | 1 | Dec 24, 2007 | clinicaltrials |
Data updated 23 days agoSource updated Aug 9, 2010source: clinicaltrials